A Federal Adaptive, On-Demand Pharmaceutical Manufacturing Initiative
Summary
The COVID-19 pandemic has highlighted the urgent need to address lags in American pharmaceutical manufacturing. An investment of $5 billion over five years will improve U.S. pharmaceutical manufacturing infrastructure, including the development of new technologies that will enable the responsive, end-to-end, on-demand production of up to half of the Food and Drug Administration (FDA) list of 223 essential medicines by year two, and the entire portfolio by year five. Spearheading improvements in domestic manufacturing capacity, coupled with driving the advancement of new adaptive, on-demand, and other advanced medicine production technologies will ensure a safe, responsive, reliable, and affordable supply of quality medicines, improving access for all citizens, including vulnerable populations living in underserved urban communities, rural areas, and tribal territories.
Understanding the implications of climate change in agriculture and forestry is crucial for our nation to forge ahead with effective strategies and outcomes.
In the quest for sustainable energy and materials, biomass emerges as a key player, bridging the gap between the energy sector and the burgeoning U.S. and regional bioeconomies.
In the last decade, the U.S. has made significant investments to address the wildfire crisis, including the historic investments in hazardous fuels reduction through the IRA and IIJA.
The widespread adoption of conservation agricultural practices to protect soils is key to ensuring food security and water quality for current and future generations in the United States.